Pages
- About UK-CAB
- Community representatives
- Contact UK-CAB
- Full Sitemap
- Membership terms
- Site map
- UK-CAB documents and policies
- Administration
- Appeals
- BHIVA guidelines writing groups - background
- Community representation
- Copyright policy
- Disclaimer
- Governance
- Meeting organisation
- Membership terms
- Privacy policy
- UK-CAB message board user agreement and posting rules
- UK-CAB representation at pharmaceutical company Community Advisory Boards
- UK-CAB Funders
- UK-CAB steering group
- Contact UK-CAB
- Join the UK-CAB
- Meetings
- Message Boards
- Message boards user guide
- Attaching a document
- Buttons and features
- Changing your email address
- Communicating with other members
- Getting messages by email
- Managing your personal details
- Message board jargon
- Printing messages
- Privacy and confidentiality
- Reading messages
- Setting a password reminder
- Signing in to the message boards
- Writing messages
- Resources
- Clinical trials
- Clinical trials - a guide for CAB members
- Clinical trials - a guide for CAB members (page 10)
- Clinical trials - a guide for CAB members (page 11)
- Clinical trials - a guide for CAB members (page 12)
- Clinical trials - a guide for CAB members (page 13)
- Clinical trials - a guide for CAB members (page 14)
- Clinical trials - a guide for CAB members (page 15)
- Clinical trials - a guide for CAB members (page 16)
- Clinical trials - a guide for CAB members (page 17)
- Clinical trials - a guide for CAB members (page 18)
- Clinical trials - a guide for CAB members (page 19)
- Clinical trials - a guide for CAB members (page 2)
- Clinical trials - a guide for CAB members (page 20)
- Clinical trials - a guide for CAB members (page 21)
- Clinical trials - a guide for CAB members (page 22)
- Clinical trials - a guide for CAB members (page 3)
- Clinical trials - a guide for CAB members (page 4)
- Clinical trials - a guide for CAB members (page 5)
- Clinical trials - a guide for CAB members (page 6)
- Clinical trials - a guide for CAB members (page 7)
- Clinical trials - a guide for CAB members (page 8)
- Clinical trials - a guide for CAB members (page 9)
- Clinical trials and other research with community representation organised by UK-CAB
- Is a clinical trial right for me?
- Where to find information on clinical trials
- Clinical trials - a guide for CAB members
- Factsheets
- Treatment guidelines
- Clinical trials
- UK Community Advisory Board
- UK-CAB members
Posts
- Category: Background reading
- Hepatitis C and HCV/HIV Coinfection - from NATAP (June 2002)
- The Body: ACRIA - Treatment Issues for Women
- Preparation material for the fourth meeting
- Women and HIV
- Reading Is Believing? A Guide to Clinical Trial Reports
- MRC HIV Trials
- Thinking it Over: Is a Clinical Trial Right for Me?
- A Guide for HIV/AIDS Community Advocates
- An Assay is a Test Or How to Talk to Real People
- Category: Meetings
- UK-CAB41: TB and HIV
- UK-CAB40: Gender and HIV Research
- UK-CAB 42: Diagnostics
- Loss to follow up study
- CAB 41: meeting report
- UK-CAB 40: Gender and HIV research
- UK-CAB 39: London HIV drug prescribing and Hepatitis C
- CAB37 Meeting report
- CAB38; HIV and the brain
- UK-CAB 37; Treatment as prevention
- UK-CAB 36 - Making the most of your GP
- UK-CAB 35 - Early diagnosis and primary infection
- UK-CAB 34 - Training: clinical trials and databases
- UK-CAB 33 - African treatment issues and late diagnosis
- UK-CAB 32 - Training: advocacy introduction
- UK-CAB 31 - Ageing and HIV
- UK-CAB 30 - Testing
- UK-CAB 29 - Resistance revisited
- UK-CAB 28 - Late presenters
- UK-CAB 27 - Transition from paediatric care to adult services
- UK-CAB 26 - TB and HIV - reporting adverse drug reactions - Theratechnologies
- UK-CAB 25 - Reading study results - D:A:D study - BHIVA treatment guidelines - GSK
- UK-CAB 24 - BHIVA 2007 clinical audit - microbicides - PEPSE - PrEP - Pfizer
- UK-CAB 23 - Access to treatment for migrants and people facing deportation - Roche
- UK-CAB 22 - HIV testing and monitoring
- UK-CAB 20 - London HIV commissioning - renal toxicity - Gilead
- UK-CAB 19 - BHIVA standards project
- UK-CAB 18 - HIV related dementia
- UK-CAB 17 - Cancer and HIV - Gilead
- UK-CAB 16 - HIV related brain impairment - SMART study - Tibotec
- UK-CAB 15 - Treatment access in eastern Europe - hepatitis C coinfection - Pfizer
- UK-CAB 14 - MRC Clinical Trials Unit - Roche
- UK-CAB 13 - Introduction to immunology - entry inhibitors
- UK-CAB 12 - Children and HIV - UK treatment guidelines
- UK-CAB 11 - Community participation in preventive HIV vaccine trials
- UK-CAB 10 - Introduction to statistics 3 - AIDS 2004 conference
- UK-CAB 9 - Vaccines and microbicides - Tibotec
- UK-CAB 8 - Introduction to statistics 2 - BMS
- UK-CAB 7 - Introduction to statistics 1 - Gilead
- UK-CAB 6 - IAS conference feedback - GlaxoSmithKline
- UK-CAB 5 - Access to treatment - TB and HIV - Roche
- UK-CAB 4: Friday 31 January 2003
- UK-CAB 3: Friday 25 October 2002
- UK-CAB 2: Friday 2 Aug 2002
- CAB 1: Friday 31 May 2002
- Category: Meeting Reports
- UK-CAB 39: meeting report
- UK-CAB 38 Meeting Report
- UK-CAB 37 Meeting report
- UK-CAB 36 Meeting report
- UK-CAB 35 - Meeting report
- UK-CAB 34 - Meeting report
- UK-CAB 33 - Meeting report
- UK-CAB 32 - Meeting report
- UK-CAB 31 - Meeting report
- UK-CAB 30 - Meeting Full Report
- UK-CAB 30 - Meeting Summary Report
- UK-CAB 29 - Meeting report
- UK-CAB 28 - Meeting report
- UK-CAB 27 - Meeting report
- UK-CAB 26 - Meeting Report
- UK-CAB 25 - Meeting Report
- UK-CAB 24 - Meeting report
- UK-CAB 23 - Meeting Report
- UK-CAB 22 - Meeting Report
- UK-CAB 21 - Meeting Report
- UK-CAB 21 - African treatment issues - Merck
- UK-CAB 20 - Meeting Report
- UK-CAB 19 - Meeting Report
- UK-CAB 18 - Meeting Report
- UK-CAB 7 - Meeting Report
- UK-CAB 6 - Meeting report
- UK-CAB 5 - Meeting Report
- UK-CAB 4 - Meeting Report
- UK-CAB 3 - Meeting Report
- UK-CAB 2 - Meeting Report
- Category: News
- Category: Presentations
- Category: Uncategorized
Plugin by dagondesign.com